Karen S. Gustafson, MD, PhD

Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Call 800-789-7366
Penn Medicine Provider

About me

  • Associate Professor of Clinical Pathology and Laboratory Medicine

My education and training

  • Medical School: University of Minnesota Medical School
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Gustafson is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Almasri B, Gustafson KS, Husson MA, Shanti RM, France K Asymptomatic bilateral facial swelling , J Am Dent Assoc, 154(3): 2023,260-265

Yu GH, Glaser LJ, Gustafson KS Role of Ancillary Techniques in Fluid Cytology , Acta Cytologica, 64: 2020,52-62

Vijayvergia, N., Boland, P. M., Handorf, E., Gustafson, K. S., Gong, Y., Cooper, H. S., Sheriff, F., Astsaturov, I. A., Cohen, S. J., Engstrom, P. F. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: A Fox Chase Cancer Center pilot study. , British Journal of Cancer, 115(5): 2016,564-570

Kaczmar, J.M., Gustafson, K.S., Wong, Y.N., Minniti, C.J., Sandilya, V.K., Sprandio, J.D., Chertock, Y., Hart, C., Hall, M.J. Tumor genomic profiling (TGP) in metastatic colorectal cancer (CRC): Bridging the community and the tertiary cancer center through genomic consultation (GC). , Journal of Clinical Oncology, 34(4): 2016

Zih, F.S., Kulkarni, N., Escalante, D.A., Meade, C., Osevala, N., Zibelman, M., Movva, S., Gustafson, K.S., Wu, H., Reddy, S., Lango, M., Olszanski, A.J., Farma, J. Molecular profiling and clinical outcomes in malignant melanoma: Experience at a NCI-designated cancer center. , Annals of Surgical Oncology, 23: 2016

Farma, J., Kulkarni, N., Escalante, D.A., Meade, C., Osevala, N., Zibelman, M., Gustafson, K.S., Wu, H., Lango, M., Reddy, S., Movva, S., Olszanski, A.J., Zih, F.S. Molecular profiling and clinical outcomes in patients with in-transit recurrence of melanoma. , Annals of Surgical Oncology , 23: 2016

Vijayvergia, N., Cohen, S.J., Boland, P.M., Gustafson, K.S., Sherrif, F., Cooper, H., Astaturov, I., Engstrom, P.F. Molecular profiling defines subsets of neuroendocrine tumors (NETs) with aggressive disease: A Fox Chase Cancer Center (FCCC) study. , Pancreas, 45(3): 2016,469-470

Shih J, Bashir B, Gustafson KS, Andrake MA, Dunbrack RL, Goldstein LJ, Boumber Y. CSI: Cancer Signature Investigation: ERBB2 (HER2)-activating mutation and amplification-positive breast carcinoma mimicking lung primary. , J Natl Compr Canc Netw, 13(8): 2015,947-52

Vijayvergia, N., Boland, P. M., Cohen, S. J., Gustafson, K. S., Cooper, H. S., Astsaturov, I. A., Engstrom, P. F. Molecular profiling of neuroendocrine tumors (NETs): The Fox Chase Cancer Center (FCCC) experience. , Journal of Clinical Oncology, 33(3): 2015

Vijayvergia, N., Boland, P. M., Gustafson, K. S., Sheriff, F., Cooper, H. S., Cohen, S. J., Astsaturov, I. A., Engstrom, P. F. Molecular profiling of advanced stage neuro endocrine tumors (NETs): The Fox Chase Cancer Center (FCCC) experience. , Pancreas, 44(2): 2015